Thursday, 3 April 2014

HIV Therapeutics Market To 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations And Stringent Healthcare Spending To Suppress Market Growth

HIV Therapeutics Market To 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations And Stringent Healthcare Spending To Suppress Market Growth

The leading business intelligence provider GBI Research has released its latest research report, entitled “HIV Therapeutics Market to 2019 – Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth”. The report provides insights into the HIV (Human Immunodeficiency Virus) therapeutics market including market forecasts up to 2019. It provides an in-depth analysis of the major marketed products, as well as insights into the HIV therapeutics R&D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global HIV therapeutics market. The report analyzes the market for HIV therapeutics in eight major markets of the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), Japan and Canada. The report discusses the global pipeline for all the HIV molecules across various stages of development. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research found that the HIV therapeutics market in the top seven markets was valued at $14.3 billion in 2012 and is projected to witness growth of 1.9% during the 2012–2019 forecast period to reach $16.3 billion.

Browse Full Report With TOC:


The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for HIV.

The report covers and includes:

A brief introduction to HIV, including the symptoms, pathogenesis, risk factors and diagnosis
In-depth analysis of major glucose-lowering drugs for HIV, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
Comprehensive review of the pipeline for HIV therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy, Spain and Canada
Discussion of the drivers and barriers for market growth

Download Full Report with TOC: 

Reasons to Buy

The report will enhance your decision-making capability. It will allow you to:

Align your product portfolio to the markets with high growth potential.
Develop market-entry and market expansion strategies by identifying the potential region and HIV/AIDS therapeutics market segments poised for strong growth.
Create a more tailored country strategy through the understanding of key drivers and barriers of the global HIV/AIDS therapeutics market.
Develop key strategic initiatives by understanding the key focus areas and top selling products of leading companies.
Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents 

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 10
2.1 Disease Introduction 10
2.2 Route of HIV Transmission 11
2.3 Etiology 11
2.4 Classification of HIV-1 Subtypes 12
2.5 Pathophysiology 12
2.5.1 HIV-1 Replication Cycle 13
2.5.2 Mechanism of CD4 T-Cell Death 14
2.5.3 Latent Infection and Viral Persistence 15
2.6 Symptoms 15
2.7 Diagnosis 16
2.7.1 HIV Antibody Assay 16
2.7.2 Rapid HIV Antibody Test 17
2.7.3 Western Blot 17
2.7.4 HIV p24 Antigen Test 17
2.7.5 Antigen-Antibody Immunoassay 17
2.7.6 Polymerase Chain Reaction Test 17
2.7.7 HIV Home-Testing Kit 18
2.8 Disease Staging 18
2.8.1 WHO Clinical Staging 18
2.8.2 Centers for Disease Control and Prevention Classification System 20
2.8.3 Immunological Classification 20
2.9 Co-morbidities and Complications 21
2.10 Epidemiology 22
2.11 Treatment Options 23
2.11.1 Nucleoside/Nucleotide Reverse Transcriptase Inhibitor 24
2.11.2 Non-Nucleoside Reverse Transcriptase Inhibitor 24
2.11.3 Entry Inhibitor 24
2.11.4 Integrase Inhibitor 24
2.11.5 HIV-1 Protease Inhibitor 25
2.11.6 Pharmacokinetic Enhancer 25
2.12 Treatment Algorithm 25

Visit Complete Report: 

3 Marketed Products 30
3.1 Therapeutic Landscape 32
3.1.1 Multi-class Combinations 32
3.1.2 Nucleotide Reverse Transcriptase Inhibitors 36
3.1.3 Non-Nucleoside Reverse Transcriptase Inhibitor 45
3.1.4 HIV Protease Inhibitor 49
3.1.5 Integrase Inhibitor 55
3.1.6 Entry Inhibitor 57
3.2 Comparative Efficacy and Safety 60
3.2.1 Multi-class Combination 62
3.2.2 Nucleotide Reverse Transcriptase Inhibitor 62
3.2.3 Non-Nucleotide Reverse Transcriptase Inhibitor 62
3.2.4 HIV Protease Inhibitor 63
3.2.5 Integrase Inhibitor 64
3.2.6 Entry Inhibitor 64
3.3 Unmet Need 64

Contact US:    
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
Tel: +1-518-618-1030

No comments:

Post a Comment